gamifant
swedish orphan biovitrum ab (publ) - emapalumab - immune system diseases - gamifant is indicated for the treatment of paediatric patients aged under 18 years with primary haemophagocytic lymphohistiocytosis (hlh).
mentazac oral.sol 2mg/ml
ΦΑΡΜΑΖΑΚ ΑΝΩΝΥΜΗ ΦΑΡΜΑΚΕΥΤΙΚΗ ΕΜΠΟΡΙΚΗ ΒΙΟΜΗΧΑΝΙΚΗ ΕΤΑΙΡΕΙΑ Δ.Τ. pharmazac ae Ναούσης 31, Βοτανικός,, 104 47 104 47, Αθήνα 210.3418889-97 - rivastigmine hydrogen tartrate - oral.sol (ΠΟΣΙΜΟ ΔΙΑΛΥΜΑ) - 2mg/ml - rivastigmine hydrogen tartrate 3,2mg - rivastigmine
lasium caps 1,5mg/cap
gap a.e. ΑΓΗΣΙΛΑΟΥ 46, 17341 ΑΓ. ΔΗΜΗΤΡΙΟΣ 210.9310980 - rivastigmine hydrogen tartrate - caps (ΚΑΨΑΚΙΟ, ΣΚΛΗΡΟ) - 1,5mg/cap - rivastigmine hydrogen tartrate 2,4mg - rivastigmine
lasium caps 3mg/cap
gap a.e. ΑΓΗΣΙΛΑΟΥ 46, 17341 ΑΓ. ΔΗΜΗΤΡΙΟΣ 210.9310980 - rivastigmine hydrogen tartrate - caps (ΚΑΨΑΚΙΟ, ΣΚΛΗΡΟ) - 3mg/cap - rivastigmine hydrogen tartrate 4,8mg - rivastigmine
lasium caps 4,5mg/cap
gap a.e. ΑΓΗΣΙΛΑΟΥ 46, 17341 ΑΓ. ΔΗΜΗΤΡΙΟΣ 210.9310980 - rivastigmine hydrogen tartrate - caps (ΚΑΨΑΚΙΟ, ΣΚΛΗΡΟ) - 4,5mg/cap - rivastigmine hydrogen tartrate 7,2mg - rivastigmine
immitis oral.sol 2mg/ml
lavipharm ae ΑΓ.ΜΑΡΙΝΑΣ, 19002 ΠΑΙΑΝΙΑ 6691600 - rivastigmine hydrogen tartrate - oral.sol (ΠΟΣΙΜΟ ΔΙΑΛΥΜΑ) - 2mg/ml - rivastigmine hydrogen tartrate 3,2mg - rivastigmine
evertas 1,5mg/cap καψακιο, σκληρο
sanofi-aventis aebe - rivastigmine - ΚΑΨΑΚΙΟ, ΣΚΛΗΡΟ - 1,5mg/cap - ineof01389 - rivastigmine - 1.500000 mg - rivastigmine
evertas 3mg/cap καψακιο, σκληρο
sanofi-aventis aebe - rivastigmine - ΚΑΨΑΚΙΟ, ΣΚΛΗΡΟ - 3mg/cap - ineof01389 - rivastigmine - 3.000000 mg - rivastigmine
evertas 4,5mg/cap καψακιο, σκληρο
sanofi-aventis aebe - rivastigmine - ΚΑΨΑΚΙΟ, ΣΚΛΗΡΟ - 4,5mg/cap - ineof01389 - rivastigmine - 4.500000 mg - rivastigmine
evertas 6mg/cap καψακιο, σκληρο
sanofi-aventis aebe - rivastigmine - ΚΑΨΑΚΙΟ, ΣΚΛΗΡΟ - 6mg/cap - ineof01389 - rivastigmine - 6.000000 mg - rivastigmine